Marker Therapeutics - רווח למניה בשנים עשר החודשים האחרונים MRKR

Marker Therapeutics is implementing energy saving and emission filtration, strictly adhering to biohazardous waste disposal regulations in its laboratories. The net income per share over the last 12 months demonstrates a trend of profit recovery, where -0.48 describes the current status of the metric. The business success is based on the efficiency of unmodified T-cell therapy, which minimizes the risks of graft-versus-host reaction when treating leukemia.
MRKR (Marker Bio): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Developing the innovative MultiTAA platform to combat oncology requires colossal capital expenditures for Marker Therapeutics (MRKR). This metric calculates the total annual net income distributed per active share, allowing for an assessment of the real efficiency of monetizing biotechnological developments. The trend of this value signals the company's transition to the self-sufficiency stage. By analyzing the TTM net income per share, an investor determines the inflection point of the business's fundamental profitability.